stockrowPrivia Health Group, Inc.
PRVA Healthcare Health Information Services
Privia Health Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 22.3% from fiscal 2024.
- Revenue
- +13.2%
- EPS
- +83.3%
- Free cash flow
- −44.4%
Quarter to September 2026, against a year earlier
Follow PRVA
Alert me
Privia Health Group, Inc. (PRVA) EPS (diluted)
Privia Health Group, Inc.'s EPS (diluted) for fiscal 2025 was $0.18, up 63.6% from $0.11 in fiscal 2024. Over the twelve months to 30 September 2026 it was $0.27. Over the past ten years it has ranged from −$1.83 (fiscal 2021) to $0.32 (fiscal 2020); the current reading is higher than 75% of that period. Privia Health Group, Inc. ranks 12th of 42 Health Information Services companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.18 | 63.64% |
| FY2024 | $0.11 | (42.11%) |
| FY2023 | $0.19 | — |
| FY2022 | −$0.08 | — |
| FY2021 | −$1.83 | — |
| FY2020 | $0.32 | 289.01% |
| FY2019 | $0.08 | — |
| FY2018 | −$0.03 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.11 | 57.14% |
| Jun 2026 | $0.07 | 250.00% |
| Mar 2026 | $0.02 | (71.43%) |
| Dec 2025 | $0.07 | 40.00% |
| 23 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| OMCL Omnicell, Inc. compare | $0.96 |
| DOCS Doximity, Inc. compare | $0.72 |
| WAY Waystar Holding Corp. compare | $0.69 |
| PRVA Privia Health Group, Inc. | $0.27 |
| GDRX GoodRx Holdings, Inc. compare | $0.04 |
| CERT Certara, Inc. compare | −$0.42 |
| SDGR Schrodinger, Inc. compare | −$0.79 |
| TDOC Teladoc Health, Inc. compare | −$0.86 |
| HTFL Heartflow, Inc. compare | −$1.83 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on PRVA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement